Trial Profile
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Giant cell tumours
- Focus Adverse reactions
- Sponsors Amgen
- 05 Sep 2023 This trial has been completed Poland according to European Clinical Trials Database record.
- 31 Jul 2023 Status changed from active, no longer recruiting to completed.
- 17 Oct 2019 Planned End Date changed from 19 Jul 2023 to 25 Jul 2023.